Get the Stockscreener App
7.50
1.19%
-0.09
After Hours:
7.49
-0.010
-0.13%
Achieve Life Sciences Inc stock is traded at $7.50, with a volume of 945.15K.
It is down -1.19% in the last 24 hours and up +19.62% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$7.59
Open:
$7.4
24h Volume:
945.15K
Relative Volume:
0.54
Market Cap:
$769.94M
Revenue:
-
Net Income/Loss:
$-51.99M
P/E Ratio:
-6.7234
EPS:
-1.1155
Net Cash Flow:
$-45.31M
1W Performance:
+12.44%
1M Performance:
+19.62%
6M Performance:
+76.89%
1Y Performance:
+194.12%
1-Day Range:
$7.2701
$7.54
1-Week Range:
$6.51
$7.60
52-Week Range:
$2.545
$7.60
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
7.50 | 779.18M | 0 | -51.99M | -45.31M | -1.1155 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Achieve Life Sciences (ACHV) draws new passive holder near 10% - Stock Titan
Achieve Life Sciences Inc (ACHV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Achieve Life SciencesEnters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock - tradingview.com
Achieve Life Sciences (ACHV) launches $150M at-the-market stock program - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV): When Will It Breakeven? - moomoo.com
Achieve Life Sciences, Inc. (NASDAQ:ACHV): Is Breakeven Near? - simplywall.st
(08/14/26) ACHV: A Speculative Trade in the Biotech Sector - moneyshow.com
Janus Henderson Group (ACHV) reports 5,502,064 Achieve Life shares under management - Stock Titan
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says - marketscreener.com
Achieve Life Sciences, Inc. Stock 12‑Month Price Target Cut to $13.83, Implies 107% Upside - tradingview.com
Achieve Life Sciences (NASDAQ:ACHV) Hits New 12-Month HighHere's Why - MarketBeat
Achieve stock gains Overweight at Morgan Stanley (ACHV:NASDAQ) - Seeking Alpha
HC Wainwright Has Optimistic Outlook of ACHV Q3 Earnings - MarketBeat
ACHV Initiates Coverage On by Morgan Stanley -- Rating Set to Ov - GuruFocus
Morgan Stanley Initiates Achieve Life Sciences at Overweight, With $13 Price Target - marketscreener.com
Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit. - webull.com
Morgan Stanley initiates Achieve Life Sciences stock at overweight By Investing.com - Investing.com Nigeria
Morgan Stanley initiates Achieve Life Sciences stock at overweight - Investing.com
H.C. Wainwright reiterates Achieve Life Sciences stock rating at buy By Investing.com - Investing.com Canada
Research Analysts Set Expectations for ACHV FY2028 Earnings - MarketBeat
Achieve Life Sciences Releases Q2 2026 Financial Results - AlphaStreet
ACHIEVE LIFE SCIENCES, INC. 6M 2026: Net loss $(84.9)M, EPS $(1.15) — 10-Q Summary - tradingview.com
Achieve Life Sciences (ACHV) swings to larger $84.9M loss on warrant costs - Stock Titan
Achieve Life Sciences (NASDAQ: ACHV) posts larger Q2 2026 loss but secures $354M financing - Stock Titan
Achieve Life Sciences Q2 Results: EPS misses estimate, losses widen - scanx.trade
Achieve Life Sciences (NASDAQ:ACHV) Posts Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Achieve Life Sciences (ACHV) Advances Cytisinicline Commercializ - GuruFocus
Achieve's Cytisinicline Study Finds 24.4% Abstinence vs. 15.8% Placebo - Stock Titan
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates - sahmcapital.com
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Achieve Life Sciences (ACHV) - The Globe and Mail
Achieve Life Sciences Inc (ACHV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Achieve Life Sciences Inc expected to post a loss of 16 cents a shareEarnings Preview - tradingview.com
Achieve Life Sciences names manufacturing, quality executives - Investing.com
Achieve Life Sciences Announced Granting of New Hire Inducement Awards - marketscreener.com
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality - marketscreener.com
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Achieve Life Sciences (ACHV) Expected to Post Earnings on Thursday - MarketBeat
Achieve Life Sciences (ACHV) director gets option and RSU awards - Stock Titan
Franklin Resources (ACHV) group discloses 8.3% Achieve Life Sciences stake via funds - Stock Titan
Achieve Life Sciences Inc (ACHV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACHV|Achieve Life Sciences Inc|Price:6.185|Chg%:+0.085 - TradingKey
BlackRock, Inc. (ACHV) discloses 5.1% beneficial stake in Achieve Life Sciences - Stock Titan
ACHV|Achieve Life Sciences Inc|Price:6.670|Chg%:+0.200 - TradingKey
Achieve Life Sciences Inc (ACHV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Achieve Life Sciences, Inc. Revenue Breakdown – NASDAQ:ACHV - TradingView
Achieve Life Sciences Inc (ACHV) Income Statement - TradingKey
Achieve Life Sciences Inc (ACHV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Achieve Life Sciences, Inc. Revenue Breakdown – SWB:SP4P - TradingView
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
1.80%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):